CP and idiopathic pulmonary fibrosis: A study, performed in 2003 [81], demonstrated that administration of TM induced a reduction in serum ceruloplasmin leading to a corresponding reduction of lung fibrosis in a mouse model of bleomycin-induced IPF, paving the way for a clinical trial on IPF patients unresponsive to other therapies (NCT00189176) (Table 2).